Page 85 - Haematologica - Vol. 105 n. 6 - June 2020
P. 85
PRIMA-1Met and AZA combination in TP53-mutant MDS/AML
A
B
C
D
E
Figure 2. The combination of PRIMA-1Met (APR-246, APR) and azacitidine (AZA) pro- motes G0/G1 arrest and apoptosis in various TP53- mutated acute myeloid leukemia (AML) cell lines. (Left) Percentage of Annexin V-positive cells at day 3 post treatment with IC10 APR, IC50 AZA, or the combination of these two drugs at these same concentrations. (Right) Proportion of cells in G0/G1, S, or G2/M phase 24 hours after treatment with IC10 APR, IC50 AZA or the combination of these two drugs at these same concentrations. (A) SKM1, (B) K562, (C) KG1a, (D) THP-1, and (E) HL60 cell lines. *P<0.05, **P<0.01.
haematologica | 2020; 105(6)
1543
